The Schall Law Firm is investigating claims on behalf of investors of AstraZeneca PLC concerning potential violations of securities laws. The investigation focuses on whether the company issued false or misleading statements or failed to disclose information pertinent to investors regarding the efficacy of its treatments. This legal scrutiny follows a significant negative market reaction to a recent clinical trial disclosure, raising concerns about potential investor losses.

On July 9, 2026, AstraZeneca revealed that its Phase-3 CARDIO-TTransform trial of Wainua, an amyloid cardiomyopathy treatment, failed to achieve its primary endpoint. Following this announcement, the company’s American Depositary Shares (ADS) fell by 5.7% on the same day. The decline in stock price has prompted the law firm to examine whether investors have suffered damages due to possible federal securities violations.

Investigation Details

The Schall Law Firm, a national shareholder rights litigation firm, is probing the circumstances surrounding the trial failure and the company's disclosures. Investors who purchased AstraZeneca securities are advised to contact the firm to discuss their rights and potential remedies. The firm represents investors globally and specializes in securities class action lawsuits and shareholder rights litigation.

Key Event Data

Pomerantz LLP is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following the failure of a key clinical trial. On July 9, 2026, Ionis disclosed that the Phase-3 CARDIO-TTRansform trial of Wainua, an amyloid cardiomyopathy treatment developed in collaboration with AstraZeneca, did not meet its primary endpoint. The primary endpoint measured the reduction of combined cardiovascular death and recurrent events. Following this disclosure, Ionis's stock price fell $20.19 per share, or 23.9%, to close at $64.27 per share on July 9, 2026.

The investigation concerns whether Ionis and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Pomerantz LLP is examining whether the company made materially false or misleading statements to investors prior to the disclosure. The Wainua CARDIO-TTRansform study was the largest trial in the ATTR cardiomyopathy population. AstraZeneca had previously positioned the treatment as a key contributor toward its stated "$80 billion 2030 ambition."

Investors who purchased IONS shares and suffered losses are encouraged to check their eligibility to recover losses. Pomerantz LLP advises affected investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The firm handles investigations on a contingency basis with no upfront costs. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as a premier firm in corporate, securities, and antitrust class litigation.